| Literature DB >> 23342240 |
Raquel Cuchacovich1, Rodolfo Perez-Alamino, Ignacio Garcia-Valladares, Luis R Espinoza.
Abstract
Psoriatic arthritis is a common systemic inflammatory disorder, which in addition to skin and nail involvement may be associated with peripheral and axial joint involvement, enthesitis, dactylitis, and important comorbidities - especially cardiovascular morbidity. Better insights into the involved pathogenic mechanisms have resulted in an improved therapeutic armamentarium, which targets key pathways in its pathogenesis. This has resulted in significant clinical responses to newer therapeutic agents, especially those directed at inhibition of tumor necrosis factor α. Biological therapy leads to significant levels of remission, improved quality of life, and retards or improves structural radiological damage.Entities:
Keywords: T helper 17 cells; metabolic syndrome; psoriasis; psoriatic arthritis; rituximab; tumor necrosis factor α blockade
Year: 2012 PMID: 23342240 PMCID: PMC3539260 DOI: 10.1177/2040622312459673
Source DB: PubMed Journal: Ther Adv Chronic Dis ISSN: 2040-6223 Impact factor: 5.091